Abstract
Background: The management of the Metabolic Syndrome (MetS) includes lifestyle interventions (e.g. diet and exercise for weight reduction), as well as drug treatment to normalize blood pressure, high-density lipoprotein cholesterol, triglycerides and glucose values. Treatment of atherogenic dyslipidemia should comprise a primary therapeutic target since it is associated with an increased risk of cardiovascular disease.
Objective: To review the efficacy of the drugs available for the management of the dyslipidemia associated with MetS.
Methods: MEDLINE was searched up to May 10, 2009 for studies in English using the mesh – terms “metabolic syndrome”, “hypercholesterolemia”, “dyslipidemia”, “treatment”, “statins” and “cardiovascular disease” in various combinations to identify treatment strategies for the management of the dyslipidemia of the MetS.
Results/Conclusions: Several drugs have been described for the management of the dyslipidemia of the MetS, namely statins, fibrates, ezetimibe, niacin, bile acid sequestrants, cholesteryl ester transfer protein inhibitors, as well as combined treatment regimes. Although each of these may deal to some extent with some aspect of the dyslipidemia of the MetS compared with placebo, a direct comparison of all these agents has not been carried out. A head-to-head comparison between the suggested regimes could identify the mono- or combination therapy for the optimal management of dyslipidemia associated with MetS.
Keywords: Metabolic syndrome, dyslipidemia, statins, fibrates, ezetimibe, niacin, bile acid sequestrants
Current Vascular Pharmacology
Title: Targeting Dyslipidemia in the Metabolic Syndrome: An Update
Volume: 8 Issue: 4
Author(s): Kosmas I. Paraskevas, Gabriel Karatzas, Alkisti Pantopoulou, Dimitrios G. Iliopoulos and Despina Perrea
Affiliation:
Keywords: Metabolic syndrome, dyslipidemia, statins, fibrates, ezetimibe, niacin, bile acid sequestrants
Abstract: Background: The management of the Metabolic Syndrome (MetS) includes lifestyle interventions (e.g. diet and exercise for weight reduction), as well as drug treatment to normalize blood pressure, high-density lipoprotein cholesterol, triglycerides and glucose values. Treatment of atherogenic dyslipidemia should comprise a primary therapeutic target since it is associated with an increased risk of cardiovascular disease.
Objective: To review the efficacy of the drugs available for the management of the dyslipidemia associated with MetS.
Methods: MEDLINE was searched up to May 10, 2009 for studies in English using the mesh – terms “metabolic syndrome”, “hypercholesterolemia”, “dyslipidemia”, “treatment”, “statins” and “cardiovascular disease” in various combinations to identify treatment strategies for the management of the dyslipidemia of the MetS.
Results/Conclusions: Several drugs have been described for the management of the dyslipidemia of the MetS, namely statins, fibrates, ezetimibe, niacin, bile acid sequestrants, cholesteryl ester transfer protein inhibitors, as well as combined treatment regimes. Although each of these may deal to some extent with some aspect of the dyslipidemia of the MetS compared with placebo, a direct comparison of all these agents has not been carried out. A head-to-head comparison between the suggested regimes could identify the mono- or combination therapy for the optimal management of dyslipidemia associated with MetS.
Export Options
About this article
Cite this article as:
I. Paraskevas Kosmas, Karatzas Gabriel, Pantopoulou Alkisti, G. Iliopoulos Dimitrios and Perrea Despina, Targeting Dyslipidemia in the Metabolic Syndrome: An Update, Current Vascular Pharmacology 2010; 8 (4) . https://dx.doi.org/10.2174/157016110791330861
DOI https://dx.doi.org/10.2174/157016110791330861 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Modulation of Lipoprotein-associated Phospholipase A2 (Lp-PLA2)
Current Pharmaceutical Design Pharmacologic Role of Vitamin D Natural Products
Current Vascular Pharmacology Drug Repurposing: An Emerging Tool for Drug Reuse, Recycling and Discovery
Current Drug Research Reviews Recent Patents on Biomedical Applications for the Treatment of Atherosclerosis
Recent Patents on Regenerative Medicine Virulence Potential of Staphylococcus aureus Strains Isolated from Diabetic Foot Ulcers Among Patients from Southern Poland
Current Vascular Pharmacology Future Perspectives in the Pharmacological Treatment of Atrial Fibrillation and Ventricular Arrhythmias in Heart Failure
Current Pharmaceutical Design Protection by Natural Honey Against Hyperhomocysteinemia in Rats
Vascular Disease Prevention (Discontinued) Natural Products as Anti-glycation Agents: Possible Therapeutic Potential for Diabetic Complications
Current Diabetes Reviews Cardiac Biomarkers in Acute Coronary Syndromes: A Review
Current Vascular Pharmacology The Impact of Diabetes on Mortality Among Elderly Patients Admitted for Treatment at a Hospital for Cardiovascular Disease in Southern Brazil
Current Diabetes Reviews Bioconversion of Isoflavones into Bioactive Equol: State of the Art
Recent Patents on Food, Nutrition & Agriculture Nitric Oxide and Protection against Cardiac Ischemia
Current Pharmaceutical Design Diabetic Cardiomyopathy and its Prevention by Metallothionein: Experimental Evidence, Possible Mechanisms and Clinical Implications
Current Medicinal Chemistry Ignored Avenues in Alpha-Synuclein Associated Proteopathy
CNS & Neurological Disorders - Drug Targets QT Prolongation and Safety in the Indian Population
Current Drug Safety Blood-Brain Barrier Integrity and Glial Support: Mechanisms that can be Targeted for Novel Therapeutic Approaches in Stroke
Current Pharmaceutical Design Vascular Protective Effects of Diabetes Medications that Mimic or Increase Glucagon-Like Peptide-1 Activity
Recent Patents on Cardiovascular Drug Discovery Ascorbic Acid: Its Role in Immune System and Chronic Inflammation Diseases
Mini-Reviews in Medicinal Chemistry Mechanisms of Action of Metformin in Type 2 Diabetes and Associated Complications: An Overview
Mini-Reviews in Medicinal Chemistry Mitochondrial Therapeutics for Cardioprotection
Current Pharmaceutical Design